ANAB Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -109.44% compared to AnaptysBio's net margin of 8.48%. AnaptysBio's return on equity of -236.31% beat Eli Lilly and's return on equity of 66.4%.

AnaptysBio has a consensus price target of $35.70, signalling upside risk potential of 173.77%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25.65%. Given that AnaptysBio has higher upside potential than Eli Lilly and, analysts believe AnaptysBio is more attractive than Eli Lilly and.

AnaptysBio has a beta of -0.111, which suggesting that the stock is 111.134% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. AnaptysBio pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AnaptysBio quarterly revenues are $30M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. AnaptysBio's net income of -$32.9M is lower than Eli Lilly and's net income of $970.3M. Notably, AnaptysBio's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 84.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 6.25x versus 17.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -109.44% compared to AnaptysBio's net margin of -49.65%. AnaptysBio's return on equity of -236.31% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

AnaptysBio has a consensus price target of $35.70, signalling upside risk potential of 173.77%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that NovaBay Pharmaceuticals has higher upside potential than AnaptysBio, analysts believe NovaBay Pharmaceuticals is more attractive than AnaptysBio.

AnaptysBio has a beta of -0.111, which suggesting that the stock is 111.134% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $30M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. AnaptysBio's net income of -$32.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, AnaptysBio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 6.25x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -109.44% compared to AnaptysBio's net margin of -2357.27%. AnaptysBio's return on equity of -236.31% beat Palatin Technologies's return on equity of --.

AnaptysBio has a consensus price target of $35.70, signalling upside risk potential of 173.77%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than AnaptysBio, analysts believe Palatin Technologies is more attractive than AnaptysBio.

AnaptysBio has a beta of -0.111, which suggesting that the stock is 111.134% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $30M, which are larger than Palatin Technologies quarterly revenues of $350K. AnaptysBio's net income of -$32.9M is lower than Palatin Technologies's net income of -$7.8M. Notably, AnaptysBio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 6.25x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

SIGA Technologies has a net margin of -109.44% compared to AnaptysBio's net margin of 13.43%. AnaptysBio's return on equity of -236.31% beat SIGA Technologies's return on equity of 52.07%.

AnaptysBio has a consensus price target of $35.70, signalling upside risk potential of 173.77%. On the other hand SIGA Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that AnaptysBio has higher upside potential than SIGA Technologies, analysts believe AnaptysBio is more attractive than SIGA Technologies.

AnaptysBio has a beta of -0.111, which suggesting that the stock is 111.134% less volatile than S&P 500. In comparison SIGA Technologies has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.87%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. AnaptysBio pays -- of its earnings as a dividend. SIGA Technologies pays out 47.21% of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AnaptysBio quarterly revenues are $30M, which are larger than SIGA Technologies quarterly revenues of $10M. AnaptysBio's net income of -$32.9M is lower than SIGA Technologies's net income of $1.3M. Notably, AnaptysBio's price-to-earnings ratio is -- while SIGA Technologies's PE ratio is 4.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 6.25x versus 2.45x for SIGA Technologies. Usually stocks with elevated PS ratios are considered overvalued.